IAH0968 + gemcitabine + cisplatin

IAH0968 + gemcitabine + cisplatin is a combination regimen being investigated for the treatment of **HER2-positive unresectable advanced or metastatic malignant tumors**, including cholangiocarcinoma. IAH0968 is an **afucosylated anti-HER2 monoclonal antibody** engineered for enhanced binding to FcγRIIIa, leading to increased antibody-dependent cellular cytotoxicity (ADCC) and improved anti-tumor efficacy compared to trastuzumab in preclinical models. Gemcitabine is a nucleoside analog that inhibits DNA synthesis, and cisplatin is a platinum-based chemotherapy agent that induces DNA cross-linking and apoptosis. This combination aims to exploit the immunotherapeutic targeting of HER2 with IAH0968, synergistically combined with cytotoxic chemotherapy provided by gemcitabine and cisplatin. Clinical trials are ongoing to define safety, dosing, and efficacy in this oncology population[1][3][5][7].

Other names

GC (referring specifically to the gemcitabine + cisplatin regimen)